BHC
Price
$7.20
Change
+$0.02 (+0.28%)
Updated
Dec 26 closing price
Capitalization
2.66B
60 days until earnings call
Intraday BUY SELL Signals
KHTRF
Price
$4.35
Change
-$0.05 (-1.14%)
Updated
Dec 23 closing price
Capitalization
433.09M
Intraday BUY SELL Signals
Interact to see
Advertisement

BHC vs KHTRF

Header iconBHC vs KHTRF Comparison
Open Charts BHC vs KHTRFBanner chart's image
Bausch Health Companies
Price$7.20
Change+$0.02 (+0.28%)
Volume$1.02M
Capitalization2.66B
Knight Therapeutics
Price$4.35
Change-$0.05 (-1.14%)
Volume$3.4K
Capitalization433.09M
BHC vs KHTRF Comparison Chart in %
View a ticker or compare two or three
VS
BHC vs. KHTRF commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Buy and KHTRF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (BHC: $7.18 vs. KHTRF: $4.35)
Brand notoriety: BHC: Notable vs. KHTRF: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 34% vs. KHTRF: 41%
Market capitalization -- BHC: $2.66B vs. KHTRF: $433.09M
BHC [@Pharmaceuticals: Generic] is valued at $2.66B. KHTRF’s [@Pharmaceuticals: Generic] market capitalization is $433.09M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 0 FA rating(s) are green whileKHTRF’s FA Score has 0 green FA rating(s).

  • BHC’s FA Score: 0 green, 5 red.
  • KHTRF’s FA Score: 0 green, 5 red.
According to our system of comparison, BHC is a better buy in the long-term than KHTRF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 6 TA indicator(s) are bullish while KHTRF’s TA Score has 2 bullish TA indicator(s).

  • BHC’s TA Score: 6 bullish, 4 bearish.
  • KHTRF’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, BHC is a better buy in the short-term than KHTRF.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а +5.28% price change this week, while KHTRF (@Pharmaceuticals: Generic) price change was +1.35% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.98%. For the same industry, the average monthly price growth was +12.50%, and the average quarterly price growth was +30.15%.

Reported Earning Dates

BHC is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+5.98% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHC($2.66B) has a higher market cap than KHTRF($433M). KHTRF has higher P/E ratio than BHC: KHTRF (62.66) vs BHC (7.40). KHTRF YTD gains are higher at: 20.499 vs. BHC (-10.918). BHC has higher annual earnings (EBITDA): 3.29B vs. KHTRF (54.4M). BHC has more cash in the bank: 1.31B vs. KHTRF (118M). KHTRF has less debt than BHC: KHTRF (106M) vs BHC (21B). BHC has higher revenues than KHTRF: BHC (10B) vs KHTRF (414M).
BHCKHTRFBHC / KHTRF
Capitalization2.66B433M615%
EBITDA3.29B54.4M6,046%
Gain YTD-10.91820.499-53%
P/E Ratio7.4062.6612%
Revenue10B414M2,415%
Total Cash1.31B118M1,108%
Total Debt21B106M19,811%
FUNDAMENTALS RATINGS
BHC vs KHTRF: Fundamental Ratings
BHC
KHTRF
OUTLOOK RATING
1..100
3250
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
4653
P/E GROWTH RATING
1..100
9897
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHC's Valuation (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for KHTRF (71) in the null industry. This means that BHC’s stock grew somewhat faster than KHTRF’s over the last 12 months.

KHTRF's Profit vs Risk Rating (84) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that KHTRF’s stock grew similarly to BHC’s over the last 12 months.

KHTRF's SMR Rating (90) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that KHTRF’s stock grew similarly to BHC’s over the last 12 months.

BHC's Price Growth Rating (46) in the Pharmaceuticals Other industry is in the same range as KHTRF (53) in the null industry. This means that BHC’s stock grew similarly to KHTRF’s over the last 12 months.

KHTRF's P/E Growth Rating (97) in the null industry is in the same range as BHC (98) in the Pharmaceuticals Other industry. This means that KHTRF’s stock grew similarly to BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCKHTRF
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
48%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
48%
Momentum
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
38%
MACD
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
47%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
34%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
66%
Bullish Trend 3 days ago
36%
Advances
ODDS (%)
Bullish Trend 4 days ago
73%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
79%
Bearish Trend 4 days ago
27%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
57%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
34%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signal:
Gain/Loss:
KHTRF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JERIX12.160.06
+0.50%
Janus Henderson Global Real Estate I
GAOSX21.390.04
+0.19%
JPMorgan Global Allocation I
CGVYX28.440.03
+0.11%
American Funds Global Insight 529-A
MREGX15.840.01
+0.06%
BlackRock Unconstrained Equity R
VALAX29.51N/A
N/A
Al Frank Adv

BHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHC has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
-1.91%
AMRX - BHC
39%
Loosely correlated
+0.23%
VTRS - BHC
36%
Loosely correlated
+1.83%
AMPH - BHC
35%
Loosely correlated
+1.36%
HROW - BHC
27%
Poorly correlated
+2.05%
TEVA - BHC
26%
Poorly correlated
+0.63%
More

KHTRF and

Correlation & Price change

A.I.dvisor tells us that KHTRF and PLSH have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KHTRF and PLSH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KHTRF
1D Price
Change %
KHTRF100%
N/A
PLSH - KHTRF
25%
Poorly correlated
-9.09%
OVATF - KHTRF
24%
Poorly correlated
N/A
BHC - KHTRF
23%
Poorly correlated
-1.91%
ORGO - KHTRF
22%
Poorly correlated
+2.09%
ESALF - KHTRF
21%
Poorly correlated
N/A
More